Linganisha mbinu

	Tathmini ya Mgonjwa ya Ubora wa Maisha Kuhusu Kuvimbiwa	Fahirisi ya Dalili Muhimu za Gastroparesis	Kifupi cha Dodoso la Magonjwa ya Kuvimba Utumbo
Nyanja	Gastroenterolojia	Gastroenterolojia	Gastroenterolojia
Familia	Process / pipeline	Process / pipeline	Process / pipeline
Mwaka wa asili	2005	2003	2004
Mwanzilishi	Marquis, P., De La Loge, C., Dubois, D., et al.	Revicki, D. A., Rentz, A. M., Dubois, D., et al.	Guyonnet, D., Chassany, O., Ducroc, R., et al.
Aina	Self-report	Self-report	Self-report
Chanzo asilia	Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005). Development and validation of the Patient Assessment of Constipation-Quality of Life questionnaire. Scandinavian Journal of Gastroenterology, 40(5), 540–551.	Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150.	Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465.
Majina mbadala	PAC-QoL, PAC-Q	GCSI	IBDQ-32, Short IBDQ
Zinazohusiana	4	4	4
Muhtasari	The Patient Assessment of Constipation Quality of Life (PAC-QoL) is a validated, patient-reported outcome measure designed to assess the impact of functional constipation on physical, psychological, and social well-being. Developed by Marquis and colleagues in 2005, the PAC-QoL comprises 28 items organized into four domains: Physical Discomfort, Psychosocial Discomfort, Worries and Concerns, and Satisfaction. The PAC-QoL is responsive to treatment and widely used in constipation clinical trials and practice.	The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response.	The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice.